Literature DB >> 31860788

In conversation with Gerard Evan.

Paraminder Dhillon1, Gerard Evan2.   

Abstract

Gerard Evan is Head of Department and Sir William Dunn Professor at the Department of Biochemistry, University of Cambridge, UK. Driven by his innate passion to understand how things work, Gerard has devoted much of his career to understanding the molecular basis of cancer, particularly the roles played by oncogenes such as Myc. His work has helped elucidate the complex role that this gene plays in cell proliferation and apoptosis, and paved new avenues for the treatment of aggressive cancers. In this interview, Gerard provides an overview of what is known about the role of Myc in normal and cancer cells and provides a persuasive argument for the application of 'impersonalised therapy' involving Myc inhibition as part of future chemotherapeutic drug regimes.
© 2019 Federation of European Biochemical Societies.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31860788     DOI: 10.1111/febs.15121

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  4 in total

Review 1.  Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc.

Authors:  Sarah K Madden; Aline Dantas de Araujo; Mara Gerhardt; David P Fairlie; Jody M Mason
Journal:  Mol Cancer       Date:  2021-01-04       Impact factor: 27.401

Review 2.  MYC inhibitors in multiple myeloma.

Authors:  Sandra Martínez-Martín; Laura Soucek
Journal:  Cancer Drug Resist       Date:  2021-08-13

Review 3.  Tumor cell malignancy: A complex trait built through reciprocal interactions between tumors and tissue-body system.

Authors:  Jean Feunteun; Pauline Ostyn; Suzette Delaloge
Journal:  iScience       Date:  2022-04-08

Review 4.  The Provocative Roles of Platelets in Liver Disease and Cancer.

Authors:  Preeti Kanikarla Marie; Natalie W Fowlkes; Vahid Afshar-Kharghan; Stephanie L Martch; Alexey Sorokin; John Paul Shen; Van K Morris; Arvind Dasari; Nancy You; Anil K Sood; Michael J Overman; Scott Kopetz; David George Menter
Journal:  Front Oncol       Date:  2021-07-21       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.